financetom
Business
financetom
/
Business
/
Chubb Prices $1.25 Billion Senior Notes Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chubb Prices $1.25 Billion Senior Notes Offering
Aug 5, 2025 3:07 AM

05:49 AM EDT, 08/05/2025 (MT Newswires) -- Chubb ( CB ) said late Monday its subsidiary Chubb INA Holdings has priced a public offering of $1.25 billion in 4.90% senior notes due 2035.

Net proceeds from the offering are expected to be used for general corporate purposes, including repaying part of the company's outstanding $1.5 billion 3.35% senior notes maturing on May 3, 2026.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EXPLAINER-Everything you need to know about the 2025 Super Bowl 
EXPLAINER-Everything you need to know about the 2025 Super Bowl 
Dec 16, 2024
(Changes headline. No changes to text) Dec 16 (Reuters) - The NFL season is in its home stretch, and with the playoff picture becoming more clear fans are sizing up their team's prospects for making it to the Super Bowl, arguably the biggest single event in U.S. sports with a huge global audience. Here's everything you need to know about...
Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia
Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia
Dec 16, 2024
08:52 AM EST, 12/16/2024 (MT Newswires) -- Reviva Pharmaceuticals ( RVPH ) said Monday that preliminary topline data from a phase 3 study of brilaroxazine in patients with schizophrenia was positive as it demonstrated robust broad-spectrum efficacy that was sustained for more than one year. The biopharmaceutical company also said brilaroxazine was generally well tolerated with no single side effect...
PepGen Receives FDA Clinical Hold in Trial of Potential Duchenne Muscular Dystrophy Treatment; Shares Fall
PepGen Receives FDA Clinical Hold in Trial of Potential Duchenne Muscular Dystrophy Treatment; Shares Fall
Dec 16, 2024
08:53 AM EST, 12/16/2024 (MT Newswires) -- PepGen ( PEPG ) said Monday it has received a Food and Drug Administration clinical hold notice for its investigational new drug application to initiate a phase 2 trial of PGN-EDO51, a potential treatment for Duchenne muscular dystrophy. The regulator will send an official clinical hold letter within 30 days, the company said....
Starbucks Expands Parental Leave for US Store Employees
Starbucks Expands Parental Leave for US Store Employees
Dec 16, 2024
08:56 AM EST, 12/16/2024 (MT Newswires) -- Starbucks ( SBUX ) will increase paid parental leave for US store employees working at least 20 hours per week, according to a website message from the company's Chief Executive Brian Niccol on Monday. Niccol said that starting in March, the company will allow fully paid leave of up to 18 weeks for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved